Active Filter(s):
Details:
The proceeds will support the clinical advancement of Corsair’s lead product candidate, a prodrug of treprostinil delivered in a proprietary transdermal patch to treat Pulmonary Arterial Hypertension (PAH).
Lead Product(s): Treprostinil Prodrug
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Junson Capital
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 20, 2023